1376 related articles for article (PubMed ID: 27245147)
21. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
[TBL] [Abstract][Full Text] [Related]
22. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
[TBL] [Abstract][Full Text] [Related]
23. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer.
Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
[TBL] [Abstract][Full Text] [Related]
24. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
[No Abstract] [Full Text] [Related]
25. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
[TBL] [Abstract][Full Text] [Related]
26. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
27. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts.
Hegab AE; Ozaki M; Kameyama N; Gao J; Kagawa S; Yasuda H; Soejima K; Yin Y; Guzy RD; Nakamura Y; Ornitz DM; Betsuyaku T
J Pathol; 2019 Oct; 249(2):193-205. PubMed ID: 31090071
[TBL] [Abstract][Full Text] [Related]
28. E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.
Watanabe Miyano S; Yamamoto Y; Kodama K; Miyajima Y; Mikamoto M; Nakagawa T; Kuramochi H; Funasaka S; Nagao S; Sugi NH; Okamoto K; Minoshima Y; Nakatani Y; Karoji Y; Ohashi I; Yamane Y; Okada T; Matsushima T; Matsui J; Iwata M; Uenaka T; Tsuruoka A
Mol Cancer Ther; 2016 Nov; 15(11):2630-2639. PubMed ID: 27535969
[TBL] [Abstract][Full Text] [Related]
29. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of Primary Drug Resistance in
Malchers F; Ercanoglu M; Schütte D; Castiglione R; Tischler V; Michels S; Dahmen I; Brägelmann J; Menon R; Heuckmann JM; George J; Ansén S; Sos ML; Soltermann A; Peifer M; Wolf J; Büttner R; Thomas RK
Clin Cancer Res; 2017 Sep; 23(18):5527-5536. PubMed ID: 28630215
[No Abstract] [Full Text] [Related]
31. Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors.
Liu Y; Peng X; Guan X; Lu D; Xi Y; Jin S; Chen H; Zeng L; Ai J; Geng M; Hu Y
Eur J Med Chem; 2017 Jan; 126():122-132. PubMed ID: 27750146
[TBL] [Abstract][Full Text] [Related]
32. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment.
Kang J; Choi YJ; Seo BY; Jo U; Park SI; Kim YH; Park KH
Sci Rep; 2019 Jun; 9(1):8726. PubMed ID: 31217507
[TBL] [Abstract][Full Text] [Related]
33. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
[TBL] [Abstract][Full Text] [Related]
34. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
[TBL] [Abstract][Full Text] [Related]
35. Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients.
Choi CH; Chung JY; Kim JH; Kim BG; Hewitt SM
J Transl Med; 2016 May; 14(1):124. PubMed ID: 27154171
[TBL] [Abstract][Full Text] [Related]
36. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
37. FGF signaling network in the gastrointestinal tract (review).
Katoh M; Katoh M
Int J Oncol; 2006 Jul; 29(1):163-8. PubMed ID: 16773196
[TBL] [Abstract][Full Text] [Related]
38. Expression and localization of fibroblast growth factors and fibroblast growth factor receptors in the developing rat kidney.
Cancilla B; Ford-Perriss MD; Bertram JF
Kidney Int; 1999 Dec; 56(6):2025-39. PubMed ID: 10594778
[TBL] [Abstract][Full Text] [Related]
39. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
Gozgit JM; Wong MJ; Moran L; Wardwell S; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Clackson T; Rivera VM
Mol Cancer Ther; 2012 Mar; 11(3):690-9. PubMed ID: 22238366
[TBL] [Abstract][Full Text] [Related]
40. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
